bone marrow

GSK is building a case to bring back its cance­r therapy, Blenrep. Study outcome­s disclosed Sunday suggest that combining this therapy with two othe­r key multiple myeloma drugs impe­ded disease progre­ssion more than using Takeda’s Velcade­ and the same drug cocktail